

**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Vassar Health Connecticut, Inc. d/b/a Sharon Hospital</p> <p>2. 50 Hospital Hill Road Sharon, CT 06069</p>	<p>In accordance with letters dated April 18, 2017, and June 26, 2017.</p>	<p>4. Expiration Date: June 30, 2025</p>
	<p>3. License number: 06-08020-02 is amended in its entirety to read as follows:</p>	<p>5. Docket No.: 030-01272 Reference No.:</p>

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 250 millicuries total	C. For any iodine-131 study or procedure permitted by 10 CFR 35.300.

**CONDITIONS**

10. Licensed material may be used or stored at the licensee's facilities located at 50 Hospital Hill Road, Sharon, Connecticut.
11. The Radiation Safety Officer (RSO) for this license is Thomas J. Larocca, M.S., D.A.B.R.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number  
06-08020-02

Docket or Reference Number  
030-01272

Amendment No. 29

12. Licensed material shall only be used by, or under the supervision of:

A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.

B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User(M.D.,D.O.,etc.)

Material and Use

Jon M. Lewis, M.D.	10 CFR 35.100,10 CFR 35.200
Donald J. Soucier, D.O.	10 CFR 35.100,10 CFR 35.200
Phillip Amatulle, M.D.	10 CFR 35.100,10 CFR 35.200
Jonathan Crystal, M.D.	10 CFR 35.100,10 CFR 35.200
Bruce R. Gendron, M.D.	10 CFR 35.100,10 CFR 35.200
Russell Karp, M.D.	10 CFR 35.100,10 CFR 35.200
Benjamin D. Seckler, M.D.	10 CFR 35.100,10 CFR 35.200
David Krakowski, M.D.	10 CFR 35.100,10 CFR 35.200
Joseph C. Antonio, M.D.	10 CFR 35.100,10 CFR 35.200
Richard Friedland, M.D.	10 CFR 35.100,10 CFR 35.200
Emil Shih, M.D.	10 CFR 35.100,10 CFR 35.200
Bryan Yen, M.D.	10 CFR 35.100,10 CFR 35.200
Victor D. Gaines, M.D.	10 CFR 35.100,10 CFR 35.200; Oral administration of sodium iodide I-131
Benjamin M. Hentel, M.D.	10 CFR 35.100,10 CFR 35.200
Donald C. Lien, M.D.	10 CFR 35.100,10 CFR 35.200; Oral administration of sodium iodide I-131
Yiping Zhang, M.D.	10 CFR 35.100,10 CFR 35.200
Nancy A. Cooper, M. D.	10 CFR 35.100,10 CFR 35.200; Oral administration of sodium iodide I-131
Kathleen Llewellyn, M.D.	10 CFR 35.100,10 CFR 35.200; Oral administration of sodium iodide I-131

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**License Number  
06-08020-02Docket or Reference Number  
030-01272

Amendment No. 29

Authorized User(M.D.,D.O.,etc.)

Daniel O'Dea, M.D.

Mark Harrison, M.D.

Material and Use

10 CFR 35.100,10 CFR 35.200

10 CFR 35.100,10 CFR 35.200

13. The effective date of License Amendment 28 is the date that the license transfer described in the letter dated February 22, 2017 (ML17061A173), letter dated March 3, 2017 (ML17079A082), and letter dated April 20, 2017 (ML17121A505), is completed, but no later than 60 days after the NRC approval letter dated May 22, 2017.
14. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**License Number  
06-08020-02Docket or Reference Number  
030-01272

Amendment No. 29

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated February 4, 2015 [ML15054A182]
- B. Letter dated June 19, 2015 [ML15198A264]
- C. Letter dated October 1, 2015 [ML15287A218]
- D. Letter dated April 21, 2016 [ML16118A412]
- E. Letter dated October 17, 2016 [ML16334A478]
- F. Letter dated February 22, 2017 [ML17061A173]
- G. Letter dated March 3, 2017 [ML17079A082]
- H. Letter dated April 20, 2017 [ML17121A505]
- I. Email dated April 21, 2017, with attachments [ML17121A506]

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: June 27, 2017By: Robert Gallagher  
Region 1